Plain-English translation of NCT06413459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are trying to find biological markers—measurable signs in your blood or immune system—that could predict how a lung infection called Mycobacterium abscessus will progress in people with cystic fibrosis. By studying blood samples from patients at different stages of this infection, they hope to identify patterns that could help doctors catch and treat the disease earlier.
Right now, doctors don't have reliable early warning signs to predict which cystic fibrosis patients with this bacterial infection will get sicker faster. If researchers can identify these biological markers, it could help doctors personalize treatment and improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital during your regular cystic fibrosis clinic appointments. During these visits, researchers will collect blood samples and possibly other tissue samples to analyze. The study compares four groups: people with cystic fibrosis who have never had this infection, those with the infection but no lung disease, those with active lung disease from the infection, and healthy volunteers without cystic fibrosis. There is no medication to take—this is purely an observational study collecting samples to understand the disease better.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Italy
Sponsor
Ospedale San Raffaele
Collaborators
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment target
~40 participants
Started
April 2021
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nicola I Lorè, PhD
Ospedale San Raffaele
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.